Idenix Pharmaceuticals (IDIX)

[go seek]

a knee-jerk reaction on the NVS decision not to license...
will not be surprised to see IDIX move back above today's close of @2.50 in short order.

...So we get another company w/ strong anti-viral development experience to opt in. Any guesses on who Idenix may be talking to?

Gilead
Abbott
Glaxo Smith Kline
Schering
Bristol Myers Squib
Merck
Pfizer

Some of the above have very significant efforts in the HCV space that 'may' fit well with IDX184

Leadership did say the interest in IDX184 was significant.